Funding Objective: PrimeDrink Group Corp. is proceeding with a non-brokered private placement aiming to raise a minimum of $300,000 and a maximum of $5 million to support business development and general working capital needs.
Unit Structure: Each unit is priced at $1,000 and consists of 16,667 common shares and 16,667 transferable warrants, with an expected issuance of 5 million to 83.33 million common shares, thereby strengthening the company's capital base.
Warrant Terms: Each warrant allows the holder to purchase a common share at $0.06 per share for three years, providing potential appreciation opportunities for investors and enhancing market appeal.
Regulatory Approval: The private placement is subject to final approval from the Canadian Securities Exchange and other relevant regulatory bodies, ensuring compliance and mitigating investment risks.
PRME
$3.74+Infinity%1D
Analyst Views on PRME
Wall Street analysts forecast PRME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRME is 6.08 USD with a low forecast of 4.25 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast PRME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRME is 6.08 USD with a low forecast of 4.25 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 3.880
Low
4.25
Averages
6.08
High
9.00
Current: 3.880
Low
4.25
Averages
6.08
High
9.00
JPMorgan
Tessa Romero
Neutral
maintain
2025-11-18
Reason
JPMorgan
Tessa Romero
Price Target
2025-11-18
maintain
Neutral
Reason
JPMorgan analyst Tessa Romero kept a Neutral rating with no price target on Prime Medicine following a transfer of coverage. The firm says it would consider recommending the shares as the company moves closer to "value-creating milestones."
Citi
Samantha Semenkow
Neutral
downgrade
$5
2025-11-11
Reason
Citi
Samantha Semenkow
Price Target
$5
2025-11-11
downgrade
Neutral
Reason
Citi analyst Samantha Semenkow lowered the firm's price target on Prime Medicine to $4.25 from $5 and keeps a Neutral rating on the shares.
Citi
Neutral
maintain
$4 -> $5
2025-10-29
Reason
Citi
Price Target
$4 -> $5
2025-10-29
maintain
Neutral
Reason
Citi raised the firm's price target on Prime Medicine to $5 from $4 and keeps a Neutral rating on the shares. The firm adjusted biotech price targets as part of a Q3 earnings preview.
Citi
Buy
to
Neutral
downgrade
$10
2025-05-26
Reason
Citi
Price Target
$10
2025-05-26
downgrade
Buy
to
Neutral
Reason
Citi downgraded Prime Medicine to Neutral from Buy with a price target of $1.50, down from $10. The shares are trading near cash, reflecting the market's uncertainty on the company's path to potential value inflection, the analyst tells investors in a research note. The firm says Prime's cash runway supports operations only into the first half of 2026 after implementing cost-cutting measures, which is well short of management's guidance of initial in-vivo clinical data for Wilson's and Alpha-1 antitrypsin deficiency in 2027.
About PRME
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
